Lucid Diagnostics Inc (LUCD) Peer Comparison

$1.00

$0.03 (2.64%)

As on 27-Aug-2026 10:35EDT

Market cap

$184 Mln

Revenue (TTM)

$5 Mln

P/E Ratio

--

P/B Ratio

16.8

Div. Yield

0 %

Edit

	Lucid Diagnostics Inc (LUCD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	184	12,753	10,906	9,762	10,222
Revenue ($ Mln)	5	1,505	613	2,589	785
Net Profit ($ Mln)	-52.26	160.59	-188.05	222.40	41.54
Net Margin (%)	-959.76	10.67	-30.68	8.59	5.29
RoE (%)	-478.06	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.35	--	44.47	251.57
Price-To-Book	16.78	8.41	16.38	1.26	4.84

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Lucid Diagnostics Inc (LUCD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	5.45	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	6.85	483.98	127.96	1,245.50	384.30
Gross Profit	-2.84	942.44	393.22	1,343.60	347.62
Operating Expenses	49.28	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-50.69	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-52.26	203.83	-192.83	350.40	52.15
Provision for Tax	12,747.00	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-52.26	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Lucid Diagnostics Inc (LUCD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	10.93	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	0.50	210.18	135.71	2,116.80	705.49
Current Liabilities	27.52	233.78	102.33	961.30	132.66
Total Liabilities	40.45	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Lucid Diagnostics Inc (LUCD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	2.32	630.60	404.74	7,231.50	1,749.63
Current Assets	36.62	1,344.12	515.78	3,020.50	1,200.55
Total Assets	40.45	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	24.91	212.71	102.84	1,203.70	690.94
Net Current Assets	0.00	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	Lucid Diagnostics Inc (LUCD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-46.49	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-0.20	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	59.03	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Lucid Diagnostics Inc (LUCD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-182.99	11.76	-22.53	8.98	1.79
ROE (%)	-478.06	10.86	-28.10	3.04	1.97
ROA (%)	-72.75	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-959.43	13.63	-30.58	-5.99	9.87
Net Margin (%)	-959.76	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Lucid Diagnostics Inc (LUCD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	24.89	17.55	41.55	1.37	16.49
EBIT Growth (%)	5.42	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	5.43	8.72	-102.66	-30.32	400.42
EPS Growth (%)	48.28	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	-24.87	17.33	-12.65	2.19	2.16

Valuation Ratios

	Lucid Diagnostics Inc (LUCD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-1.92	68.93	-34.59	--	189.42
Price / Book Value	10.16	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-1.79	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Lucid Diagnostics Inc (LUCD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.00	0.00	0.00	0.11	0.26
Short term debt to equity ratio	2.23	0.01	0.00	0.06	0.01
Current Ratio	1.33	5.75	5.04	3.14	9.05
Quick Ratio	1.31	3.86	4.46	2.33	7.64
Interest Coverage	-2,902.28	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	Lucid Diagnostics Inc (LUCD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	19.98	12.65	22.67	17.06	20.09
Asset Turnover	0.08	0.74	0.59	0.24	0.26
Receivable days	40.67	46.54	60.95	65.39	72.41
Inventory Days	16.80	331.92	193.84	221.09	146.53
Payable days	53.54	26.16	60.19	37.02	29.05
Cash Conversion Cycle	3.94	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly